查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年胸腔引流導管的全球市場
市場調查報告書
商品編碼
1247435

2023-2030 年胸腔引流導管的全球市場

Global Chest Drainage Catheter Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

胸腔引流導管的全球市場規模預計到 2022 年將達到 2.4347 億美元，到 2030 年將達到 3.6975 億美元，在預測期內（2023-2030 年）以 5.5% 的複合年增長率增長。據預測，

胸膜引流管是插入肺和胸壁之間的胸膜腔的管子，用於排出可能積聚並導致呼吸困難的多餘液體和空氣。 該管通常穿過胸壁插入並連接到引流系統，該引流系統收集並排出體內的液體和空氣。 胸腔引流管常用於手術後、外傷後以及肺炎和肺癌等疾病。

市場動態

技術進步、自發性氣胸全球負擔的增加、胸外科和心血管外科手術的增加以及人口老齡化推動了胸腔引流導管的全球市場增長。

胸膜感染患者的增加推動了市場增長

胸膜感染最常繼發於重症肺炎或治療不當的肺炎。 然而，最近沒有實際感染的原發性胸膜感染病例數一直在增加，這可能是由於診斷影像學的進步和更早的 CT 掃描。

根據 2021 年發表在 Journal of Aspiration 上的一篇論文，胸膜疾病的發病率正在上升，估計僅在英國 (UK) 就有 3000 例胸膜疾病。 胸膜腔中存在空氣（氣胸）或液體（胸腔積液）或出現良性、惡性或感染過程通常需要干預以緩解症狀。 引流通常使用小口徑抽吸套件（通常為 6 或 8 French gauge）或插入 Seldinger 肋間引流管 (ICD) 來完成。

此外，胸腔穿刺術和植入 ICD 屬於侵入性手術，並發症的風險歷來居高不下。 胸部超聲的廣泛使用降低了並發症的發生率，如誤置、引流管未對準、出血、感染、引流管放置失敗、氣胸、手術肺氣腫、再擴張性肺水腫和死亡。

與胸腔引流管相關的風險將阻礙市場增長

然而，雖然胸腔引流導管通常被認為是安全的，但使用它們也存在一些風險。 將管子插入體內時，總會有感染的風險。 通過清潔插入部位並遵循適當的滅菌程序，可以將這種風險降至最低。 插入部位出血或導管損傷血管的風險也很小。 胸腔引流管的風險之一是它們會導致氣胸和肺萎陷。 如果導管插入不當或患者已有肺部疾病，則這種風險會增加。 如果導管脫落，可能無法有效引流胸膜腔，可能需要重新插入。

COVID-19 影響分析

COVID-19 疫情對胸腔引流管市場產生了積極影響。 COVID-19大流行對胸腔引流導管市場產生了重大影響。 需要治療呼吸系統疾病的大量 COVID-19 患者增加了對胸腔引流導管的需求，導致某些地區這些設備短缺。 此外，大流行擾亂了供應鏈，使製造商難以生產和分銷胸腔引流管。 隨著大流行的進展，對這些設備的需求持續增加，預計未來幾年市場將出現顯著增長。

內容

第 1 章市場方法論和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 增加胸部和心血管手術的數量
      • 自發性氣胸的患病率越來越高
    • 約束因素
      • 設備成本高
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • 市場上 COVID-19 的分析
    • 在 COVID-19 市場情景之前
    • 當前的 COVID-19 市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格和動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第 7 章應用

  • 心髒病學
  • 呼吸內科
  • 一般重症監護/急救護理
  • 腫瘤學和疼痛管理
  • 感染
  • 其他

最終用戶第 8 章

  • 醫院
  • 門診手術診所
  • 其他

第9章按地區

  • 北美
    • 類型
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第10章競爭格局

  • 競爭場景
  • 公司股票分析
  • 主要發展和戰略

第11章公司簡介

  • 美敦力
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Teleflex Incorporated
  • Ply Gem Holdings Inc
  • Smiths Group plc
  • Medela AG
  • ATMOS MedizinTechnik GmbH & Co. KG
  • ARGON MEDICAL
  • MAQUET Holding B.V. & Co. KG
  • LivaNova PLC
  • Cook

第12章 DataM

簡介目錄
Product Code: MD1447

Market Overview

The global chest drainage catheter market size was valued at US$ 243.47 million in 2022 and is estimated to reach US$ 369.75 million by 2030, growing at a CAGR of 5.5% during the forecast period (2023-2030).

A chest drainage catheter is a tube inserted into the pleural space, the area between the lung and the chest wall, to remove excess fluid or air that can build up and cause difficulty breathing. The tube is typically inserted through the chest wall and is connected to a drainage system that collects the fluid or air and removes it from the body. Chest drainage catheters are commonly used after surgery, trauma, or in conditions such as pneumonia or lung cancer.

Market Dynamics

Technological advancements, the increasing burden of spontaneous pneumothorax across the globe, the rise in the number of thoracic & cardiovascular surgical procedures, and the geriatric population drive the global chest drainage catheter market growth.

An increasing number of pleural infection patients drive the market growth

Pleural infection most commonly occurs as a secondary infection in severe or undertreated pneumonia. Still, recently and increasingly, the primary pleural infection has been recognized without evidence of parenchymal infection, possibly due to advances in imaging and earlier computed tomography scanning.

As per the article published in the Journal of Aspiration in 2021, the incidence of the pleural disease is rising and is estimated to be 3000 per million patients in the United Kingdom (UK) alone. The presence of air (pneumothorax) or fluid (pleural effusion) in the pleural space or the development of benign, malignant or infective processes often necessitates intervention to relieve symptoms. Drainage is routinely performed with small bore aspiration kits (usually 6 or 8 French gauge) or insertion of a Seldinger intercostal drain (ICD).

In addition, thoracocentesis and ICD insertion are invasive procedures, and the risk of complications has historically been high. Widespread thoracic ultrasound use has reduced the incidence of complications, including incorrect placement, drain displacement, bleeding, infection, failure to place the drain, pneumothorax, surgical emphysema, re-expansion pulmonary edema and death.

The risk associated with chest drainage catheters will hamper the market's growth

However, chest drainage catheters are generally considered safe, but some risks are associated with their use. Any time a tube is inserted into the body, there is a risk of infection. This risk can be minimized by providing that the insertion site is clean and that proper sterilization procedures are followed. There is a small risk of bleeding at the insertion site or of the catheter causing injury to a blood vessel. One of the risks of a chest drainage catheter is that it may cause a pneumothorax or a collapsed lung. This risk increases if the catheter is inserted improperly or the patient has pre-existing lung conditions. If the catheter becomes dislodged, it can no longer effectively drain the pleural space and may require reinsertion.

COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted the chest drainage catheter market. The COVID-19 pandemic has significantly impacted the chest drainage catheter market. The increased demand for chest drainage catheters due to the high number of COVID-19 patients requiring treatment for respiratory issues has led to a shortage of these devices in some areas. Additionally, the pandemic has caused disturbances in the supply chain, making it difficult for manufacturers to produce and distribute chest drainage catheters. The market is expected to see significant growth in the coming years as the demand for these devices continues to rise with the ongoing pandemic.

Segment Analysis

The pulmonology segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

The pulmonology segment accounts for the highest market share. Primary spontaneous pneumothorax (PSP) is the spontaneous occurrence of air in the pleural space in patients without clinically apparent lung disease. The condition is associated with smoking.

As per the article published in BMC Pulmonary Medicine in 2020, recently, the pleural catheter or chest tube was commonly connected to an analog drainage system, in which air leakage is assessed by the observation of bubbling in the water seal.

In addition, digital drainage systems provide quantitative information on air leakage (flow) in mL/min, both actual and historical, thereby providing information on air leakage patterns. The ability to forecast extended air leakage following pulmonary resection through digital monitoring of air leakage patterns may allow for early intervention.

Geographical Analysis

North America region holds the largest market share of the global Chest Drainage Catheter market

North America dominates the market for chest drainage catheters and is expected to show a similar trend over the forecast period. Technological advancements, the rising prevalence of pulmonary and cardiac disease, and active regional players in the North American region drive the market.

According to Mayo Clinic, pleural infections remain a prevalent and difficult clinical issue. The incidence of pleural effusions is estimated to be 1.5 million new cases per year in the U.S. above both congestive heart failure and diabetes, which each see 1.8 million new cases each year (400,000 new diagnoses annually). An additional 40,000 people are affected by spontaneous and iatrogenic pneumothoraces.

In addition, ICU Medical offers Pleural Catheter with Flexible Introducer, the one-of-a-kind portex flexible introducer was created to comply with contemporary trauma and emergency treatment approaches for patients with chest injuries, which forbid the use of trocars to place drains. It meets the necessity to establish chest drainage quickly and poses no threat to the patient's internal health.

Competitive Landscape

The chest drainage catheter market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Medtronic, Teleflex Incorporated, Ply Gem Holdings Inc., Smiths Group plc., Medela AG, ATMOS MedizinTechnik GmbH & Co. KG, ARGON MEDICAL, MAQUET Holding B.V. & Co. KG, LivaNova PLC and Cook Medical, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the chest drainage catheter market globally.

Teleflex Incorporated

Overview:

Teleflex is a medical technology company designed to improve the health and quality of people's lives. The company provides a broad portfolio with solutions in vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care.

Product Portfolio:

Pleur-evac Chest Drainage Systems: The Pleur-evac Chest Drainage System provides the premier chest drainage solution for thoracic, cardiovascular, trauma, and critical care, which uses the most advanced fluid management technology available.

The global chest drainage catheter market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Number of Thoracic & Cardiovascular Surgical Procedures
      • 4.1.1.2. Increasing Prevalence of Spontaneous Pneumothorax
    • 4.1.2. Restraints:
      • 4.1.2.1. High Cost of Devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Cardiology*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 7.3. Pulmonology
  • 7.4. General Intensive Care & Emergency Medicine
  • 7.5. Oncology & Pain Management
  • 7.6. Infectious Diseases
  • 7.7. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 8.3. Ambulatory Surgery Clinics
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Company Share Analysis
  • 10.3. Key Developments and Strategies
  • 10.4.

11. Company Profiles

  • 11.1. Medtronic*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Teleflex Incorporated
  • 11.3. Ply Gem Holdings Inc
  • 11.4. Smiths Group plc
  • 11.5. Medela AG
  • 11.6. ATMOS MedizinTechnik GmbH & Co. KG
  • 11.7. ARGON MEDICAL
  • 11.8. MAQUET Holding B.V. & Co. KG
  • 11.9. LivaNova PLC
  • 11.10. Cook

LIST NOT EXHAUSTIVE

12. Global Chest Drainage Catheter Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us